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Background
Th  e estrogen receptor α (ER) protein is present in over 
two-thirds of breast cancers, where it functions in the 
nucleus as a ligand-dependent transcription factor to 
drive cell proliferation, survival, and invasiveness. Endo-
crine therapies to block ER activity are the most impor-
tant systemic treatments for ER-positive breast cancers, 
though resistance is prevalent [1]. We need to understand 
the molecular determinants regulating ER DNA binding 
and activity to elucidate the mechanisms underlying this 
resistance.
Th  e advancement of chromatin immunoprecipitation 
(ChIP)-based technologies, which combine ChIP with 
microarrays or high throughput sequencing (ChIP-seq), 
has helped to identify a network of co-regulators and 
their genome-wide DNA binding sites (known as their 
cistrome) that cooperate to regulate ER DNA binding 
and transcriptional activity. Th  ese technologies have 
revealed that, in breast cancer cells, ER mostly binds to 
distal enhancers that are also enriched for Forkhead 
motifs [2-4]. Furthermore, the Forkhead protein FOXA1, 
a favorable prognostic factor that correlates with the 
luminal A breast cancer subtype and hormonal sensitivity 
[5], has been shown to act as a pioneer factor, opening 
chromatin regions for the recruitment of ER to these 
DNA binding sites [6]. However, how global the impor-
tance of FOXA1 is in mediating ER function in breast 
cancer, as well as in other target tissues and under 
diﬀ  erent ligand conditions, and what are the underlying 
factors that determine FOXA1 speciﬁ  city remain open 
questions.
The article
To more broadly investigate the genome-wide relation-
ship of ER and FOXA1 DNA-binding sites, Hurtado and 
colleagues [7] ﬁ   rst performed ChIP-seq of ER and 
FOXA1 in three diﬀ  erent breast cancer cell lines. FOXA1 
binding events were found to be dynamic and cell-line-
speciﬁ  c, a phenomenon potentially related to the insu-
lator protein CTCF. Within each cell line, a signiﬁ  cant 
overlap of over 50% was found between ER and FOXA1 
sites. FOXA1 was also found to mediate ER function in 
non-breast cancer cells and to act upstream of ER-
chromatin interactions, enabling ER binding at more 
con  densed chromatin regions. Additionally, FOXA1 was 
required to globally facilitate ER-mediated transcription, 
since downregulation of FOXA1 aﬀ  ected the transcrip-
tion of more than 95% of estrogen-regulated genes. 
Finally, FOXA1 knockdown resulted in signiﬁ  cant growth 
inhibition of MCF7 cells, substantiating the key role of 
FOXA1 in the estrogen response of breast cancer cells.
To study the ER cistromic proﬁ   le and the role of 
FOXA1 in mediating tamoxifen inhibition, estrogen-
deprived MCF-7 cells treated with estrogen or tamoxifen 
were subjected to ER ChIP-seq and gene expression 
micro  array analyses. In contrast to a previous report [8], 
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binding events similar to those induced by estrogen. 
Additionally, estrogen and tamoxifen were found to 
regulate common genes. FOXA1 knockdown showed 
that tamoxifen-ER employs similar FOXA1-dependent 
mechanisms as estrogen to interact with chromatin. 
However, the experimental setting prevented direct 
assess  ment of whether FOXA1 is required for the 
tamoxifen antiproliferative eﬀ  ects in breast cancer cells. 
Of note, in tamoxifen-resistant derivatives of MCF-7 
cells, chromatin binding proﬁ  les of both ER and FOXA1 
dramatically diﬀ  er from those of the wild-type cell line, 
and the binding occurred independently of tamoxifen 
treatment. However, ER and FOXA1 binding regions still 
signiﬁ  cantly overlapped and, most importantly, ER chro-
matin binding and cell proliferation in the tamoxifen-
resistant line still required FOXA1.
The viewpoint
Unbiased, genome-wide mapping and proﬁ   ling of ER 
interaction with chromatin and its transcriptional 
regulation activity in breast cancer have recently been 
estab  lished by leading groups in this ﬁ  eld [2-4,9,10] and 
have created a valuable resource to increase our basic 
under  standing of estrogen/ER action and to improve 
thera  peutic strategies. Th  ese studies have collectively 
demon  strated the fundamental role of FOXA1 in guiding 
and regulating ER chromatin binding events and gene 
transcription. While the recent report of Hurtado and 
colleagues [7] strongly substantiates these previous data 
and notions, its novel insights into the role of FOXA1 in 
both tamoxifen action and resistance, and into mecha-
nistic aspects of FOXA1 action, are of clinical and 
biological signiﬁ  cance.
Th   e pivotal role of FOXA1 in ER-DNA interaction and 
transcriptional activity, as well as in the growth of wild 
type MCF7 cells, points to FOXA1 as a potential thera-
peutic target for opposing ER activity and tumor growth, 
either alone or in combination with additional endocrine 
targets. Conversely, since the tamoxifen-ER interaction 
with DNA, which is a key component of tamoxifen’s 
inhibitory action on ER-dependent gene expression, was 
also found to depend tightly on FOXA1, one could argue 
that co-targeting of FOXA1 might antagonize, instead of 
enhance, the inhibitory capabilities of anti-estrogens 
such as tamoxifen. Notably, however, in tamoxifen-resis-
tant cells, the extensively altered pattern of ER binding 
and resistant cell growth phenotype both required 
FOXA1, an observation pointing again to FOXA1 as a 
therapeutic candidate. Interestingly, Lupien and colleagues 
[11] recently showed that epidermal growth factor 
stimulation of MCF7 cells induces a ligand-independent 
distinct proﬁ  le of ER binding sites that is still enriched for 
Forkhead binding sites. Th   is growth factor (GF)-speciﬁ  c 
ER cistrome dictates a unique transcriptional program 
that correlates with gene expression signatures found in 
poor-outcome as well as HER2-positive breast cancers 
[11]. Similarly, a unique ER cistrome and ER trans  crip-
tional activation were also documented upon AKT 
activation [12], and others have shown that blocking this 
pathway with a PI3K inhibitor can restore the ‘classic’ 
pattern of E2-induced gene expression [13]. Acquired 
tamoxifen resis  tance of MCF7 cells and xenografts is also 
associated with increased GF/HER1/2 signaling and a 
distinct expression proﬁ   le that correlates with growth 
factor gene expression signatures [14,15]. As aberrant 
expression/activation of GF pathways is commonly 
associated with endocrine resistance [1,15], the data 
cumulatively imply that the diﬀ   erential ER chromatin 
binding and subse  quently altered transcriptional 
program that derive from hyperactive GF signaling are 
fundamental underlying mechanisms of endocrine 
resistance. Th  e relative contri  butions to this global 
molecular switch of ER-chromatin interactions and gene 
expression provided by (1) non-genomic ER function, (2) 
additional Forkhead family members, (3) other chromatin 
remodeling factors and/or ER coregulators, (4) post-
translational modiﬁ  cation of these key factors, and (5) 
additional epigenetic modiﬁ     ca  tions are still open 
questions. However, the critical roles of FOXA1 and ER 
in this process, as shown by Hurtado and colleagues [7], 
indeed suggest that co-targeting of FOXA1 together with 
more potent ER inhibitors or degraders [11] might 
represent an improved strategy to circumvent endocrine 
resistance in breast cancer.
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